Abstract
BackgroundCertolizumab pegol (CZP), a PEGylated Fc-free anti-TNF, has demonstrated a fast response and acceptable safety profile in rheumatoid arthritis (RA).ObjectivesTo evaluate the effectiveness and safety of CZP in daily clinical...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
